1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner.
2. Thrombotic biomarkers including fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein were lower in treatment groups compared to placebo.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Prior studies, including the landmark...